XML 40 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Share (Tables)
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Schedule of basic and diluted net loss per share Basic and diluted net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. was calculated as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 

 
 

 
 

 
 

Net loss
 
$
(39,269
)
 
$
(38,440
)
 
$
(124,731
)
 
$
(57,193
)
Accretion of beneficial conversion feature on Series A preferred shares
 
—

 
(8,006
)
 
—

 
(12,006
)
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.
 
$
(39,269
)
 
$
(46,446
)
 
$
(124,731
)
 
$
(69,199
)
Denominator:
 
 
 
 
 
 
 
 
Weighted average common shares outstanding—basic and diluted
 
38,942,545

 
26,038,192

 
37,873,755

 
19,563,525

Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted
 
$
(1.01
)
 
$
(1.78
)
 
$
(3.29
)
 
$
(3.54
)
Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2018
 
2017
 
2018
 
2017
Options to purchase common shares
 
6,019,570

 
4,717,870

 
6,019,570

 
3,247,500

Warrants to purchase common shares
 
221,751

 
821,751

 
221,751

 
600,000

 
 
6,241,321

 
5,539,621

 
6,241,321

 
3,847,500